ProMIS Neurosciences Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PMN in the last 7 days.
PROMIS Neurosciences (PMN) reported Q2 2026 results on Aug. 13. It posted EPS of -$1.28, better than the -$1.39 estimate by $0.11, and revenue of $0, matching estimates. The article also cites insider purchases (7 buys, 0 sells in 6 months), institutional buying by several funds, and a median analyst price target of $18.5.
ProMIS Neurosciences (PMN) reported interim Phase I-B data for PMN310, saying it observed no ARIA-E and showed strong biomarker signals, indicating target engagement and a differentiated safety profile, according to its Q2 2026 audio transcript. The company said cash runway extends through 2027 and a pivotal readout is expected in Q1 2027.
ProMIS Neurosciences reported Q2 2026 results and an earnings call transcript. Cash and short-term investments rose to CAD 53.4 million at June 30, 2026, after a January financing. Q2 net loss was CAD 11.7 million (CAD 1.28/share). Management said funding should last through 2027 for a Q1 2027 PRECISE-AD readout for PMN310.
Recent PMN coverage spans earnings, technology and insider activity.
In the last 30 days, PMN insiders filed 1 SEC Form 4 transaction — 1 purchase ($30K) and no sales. The most active reporter was Kaplan Johanne, Chief Development Officer, with 1 filing.
The earnings beat is offset by zero reported revenue, keeping the fundamental signal mixed and likely limiting sustained upside.
Interim safety and target-engagement signals for PMN310 reduce near-term clinical risk and support funding visibility into 2027.
ProMIS Neurosciences reported Q2 2026 results and an earnings call transcript. Cash and short-term investments rose to CAD 53.4 million at June 30, 2026, after a January financing. Q2 net loss was CAD 11.7 million (CAD 1.28/share). Management said funding should last through 2027 for a Q1 2027 PRECISE-AD readout for PMN310.
Interim safety and biomarker signals reduce near-term clinical risk for PMN310, but the trial remains blinded and the key unblinded 12-month topline is not yet released.
Interim safety and biomarker signals for PMN310 reduce near-term clinical risk (ARIA-E) and support a positive setup into the unblinded 12-month readout in Q1 2027.
alphai scores every news story that mentions PMN with an AI model for sentiment and relevance, and aggregates insider trades from ProMIS Neurosciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PROMIS Neurosciences (PMN) reported Q2 2026 results on Aug. 13. It posted EPS of -$1.28, better than the -$1.39 estimate by $0.11, and revenue of $0, matching estimates. The article also cites insider purchases (7 buys, 0 sells in 6 months), institutional buying by several funds, and a median analyst price target of $18.5.
3 min readProMIS Neurosciences (PMN) reported interim Phase I-B data for PMN310, saying it observed no ARIA-E and showed strong biomarker signals, indicating target engagement and a differentiated safety profile, according to its Q2 2026 audio transcript. The company said cash runway extends through 2027 and a pivotal readout is expected in Q1 2027.
1 min readProMIS Neurosciences reported Q2 2026 results and an earnings call transcript. Cash and short-term investments rose to CAD 53.4 million at June 30, 2026, after a January financing. Q2 net loss was CAD 11.7 million (CAD 1.28/share). Management said funding should last through 2027 for a Q1 2027 PRECISE-AD readout for PMN310.
4 min readProMIS Neurosciences (Nasdaq: PMN) reported Q2 2026 results and interim six-month blinded data from its Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer’s. It said there were no ARIA-E cases among 136 safety-evaluable participants, and biomarkers pTau217 and CSF MTBR-tau243 declined. Cash was $53.4M, funding operations through 2027, with unblinded 12-month topline expected in Q1 2027.
7 min readProMIS Neurosciences Inc. (PMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights • Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzhe
6 min readKaplan Johanne (Chief Development Officer) purchased 2,280 shares of ProMIS Neurosciences Inc. (PMN) at $13.30 on 2026-08-05.
1 min readProMIS Neurosciences Inc. (Nasdaq: PMN) said it will release its second-quarter 2026 financial results for the period ended June 30, 2026 and provide a business update on Aug. 13, 2026. The company will hold an investor conference call and webcast at 4:30 p.m. ET, with a replay available afterward on its website.
1 min readBiotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readPromis Neurosciences (NASDAQ:PMN) reported interim Phase 1b safety data for PMN310 in Alzheimer’s. As of July 22, there were no ARIA-E cases in the blinded safety population and no treatment-related serious adverse events. Total ARIA was 4.4% (mild, asymptomatic ARIA-H). Biomarkers showed declines in plasma p-tau217 and CSF MTBR-tau243. Dosing runs to Dec 2026; unblinding expected early 2027.
5 min readProMIS Neurosciences reported a blinded interim safety analysis of PMN310 in an early Alzheimer’s study with 136 patients. It said no ARIA-E cases occurred by the cutoff, total ARIA incidence was 4.4% and limited to mild, asymptomatic ARIA-H. No treatment-related serious adverse events or discontinuations were reported, including in APOE4 carriers. Unblinded 12-month topline results are expected in Q1 2027.
5 min read
